
Duration of Benefit in Patients With Autoimmune Pulmonary Alveolar Proteinosis After Inhaled Granulocyte-Macrophage Colony-Stimulating Factor Therapy
Keywords: CEA; A-aDO2; alveolar-arterial oxygen difference; Ab; antibody; aPAP; autoimmune pulmonary alveolar proteinosis; AT; additional treatment; BALF; BAL fluid; CEA; carcinoembryonic antigen; Dlco; diffusing capacity of the lung for carbon monoxide; DSS; disease se